Maria Marco
Overview
Explore the profile of Maria Marco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
493
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gonzalez S, Wall R, Thomas J, Braillard S, Brunori G, Camino Diaz I, et al.
Sci Transl Med
. 2023 Dec;
15(726):eadg8105.
PMID: 38091410
Chagas disease, caused by the protozoan parasite , affects millions of people in the Americas and across the world, leading to considerable morbidity and mortality. Current treatment options, benznidazole (BNZ)...
2.
Braillard S, Keenan M, Breese K, Heppell J, Abbott M, Islam R, et al.
Sci Transl Med
. 2023 Dec;
15(726):eadh9902.
PMID: 38091406
New drugs for visceral leishmaniasis that are safe, low cost, and adapted to the field are urgently required. Despite concerted efforts over the last several years, the number of new...
3.
Thomas M, McGonagle K, Rowland P, Robinson D, Dodd P, Camino-Diaz I, et al.
J Med Chem
. 2023 Jul;
66(15):10413-10431.
PMID: 37506194
There is an urgent need for new treatments for Chagas disease, a parasitic infection which mostly impacts South and Central America. We previously reported on the discovery of GSK3494245/DDD01305143, a...
4.
McGonagle K, Tarver G, Cantizani J, Cotillo I, Dodd P, Ferguson L, et al.
Eur J Med Chem
. 2022 May;
238:114421.
PMID: 35594652
Approximately 6-7 million people around the world are estimated to be infected with Trypanosoma cruzi, the causative agent of Chagas disease. The current treatments are inadequate and therefore new medical...
5.
Thomas M, Brand S, De Rycker M, Zuccotto F, Lukac I, Dodd P, et al.
J Med Chem
. 2021 Apr;
64(9):5905-5930.
PMID: 33904304
There is an urgent need for new treatments for visceral leishmaniasis (VL), a parasitic infection which impacts heavily large areas of East Africa, Asia, and South America. We previously reported...
6.
Minana G, Gil-Cayuela C, Facila L, Bodi V, Valero E, Mollar A, et al.
Cardiol J
. 2020 Dec;
28(4):598-606.
PMID: 33346372
Background: There are no well-established predictors of recurrent ischemic coronary events after an acute coronary syndrome (ACS). Higher levels of homocysteine have been reported to be associated with an increased...
7.
Thomas M, De Rycker M, Wall R, Spinks D, Epemolu O, Manthri S, et al.
J Med Chem
. 2020 Jul;
63(17):9523-9539.
PMID: 32663005
Visceral leishmaniasis (VL) is a parasitic infection that results in approximately 26 000-65 000 deaths annually. The available treatments are hampered by issues such as toxicity, variable efficacy, and unsuitable...
8.
Minana G, Gil-Cayuela C, Bodi V, de la Espriella R, Valero E, Mollar A, et al.
Coron Artery Dis
. 2020 Feb;
31(4):378-384.
PMID: 32040026
Background: In established ischemic heart disease, the relationship between lipoprotein(a) and new cardiovascular events showed contradictory results. Our aim was to assess the relationship between lipoprotein(a) and very long-term recurrent...
9.
Wall R, Carvalho S, Milne R, Bueren-Calabuig J, Moniz S, Cantizani-Perez J, et al.
ACS Infect Dis
. 2020 Jan;
6(3):515-528.
PMID: 31967783
Available treatments for Chagas' disease and visceral leishmaniasis are inadequate, and there is a pressing need for new therapeutics. Drug discovery efforts for both diseases principally rely upon phenotypic screening....
10.
Fleau C, Padilla A, Miguel-Siles J, Quesada-Campos M, Saiz-Nicolas I, Cotillo I, et al.
J Med Chem
. 2019 Oct;
62(22):10362-10375.
PMID: 31657555
Acylaminobenzothiazole hits were identified as potential inhibitors of replication, a parasite responsible for Chagas disease. We selected compound for lead optimization, aiming to improve in parallel its anti- activity (IC...